Taking a pill seems simple.

Swallow it with some water, let the digestive system do its job, and the medicine eventually reaches the bloodstream.

That works well for many traditional drugs. But peptides are different.

A peptide may work perfectly well in a laboratory experiment and still be extremely difficult to turn into a pill. The same digestive system that helps us break down food is remarkably good at destroying peptides before they ever reach the bloodstream.

This is one reason so many peptide medicines have historically been given by injection.

Scientists are making progress on oral peptide delivery, but the problem is much harder than simply putting a peptide into a tablet.

First, What Is a Peptide?

Peptides are molecules made from amino acids connected together by peptide bonds.

Proteins are built using the same basic chemistry, although proteins are generally larger and often have more complicated three-dimensional structures.

Our bodies naturally use peptides as signaling molecules.

Peptide hormones help regulate processes involving:

• metabolism
• blood glucose
• digestion
• appetite
• growth
• cardiovascular function
• immune signaling.

Scientists have also learned how to make synthetic peptides that mimic or modify these natural signals.

That has produced an expanding class of peptide-based medicines and experimental research molecules.

The problem is that peptides have a major weakness when swallowed.

To the digestive system, many of them look a lot like food.

Your Digestive System Is Designed to Break Down Peptides

When we eat protein, our bodies do not normally absorb whole steaks, eggs, or beans directly into the bloodstream.

Digestive enzymes break proteins into smaller peptides and amino acids.

Those smaller pieces can then be absorbed and reused.

A peptide medicine swallowed as a pill enters that same environment.

The stomach contains acid and digestive enzymes. The small intestine contains additional proteases and peptidases specifically designed to break peptide bonds.

Recent reviews of oral peptide delivery identify enzymatic degradation as one of the main reasons oral peptide medicines are difficult to develop.

Imagine trying to deliver a carefully constructed paper message through a machine designed to shred paper.

The peptide has to survive long enough to reach a place where it can be absorbed.

That’s only the first problem.

Surviving Digestion Still Isn’t Enough

Suppose scientists manage to protect a peptide from digestive enzymes.

The molecule then faces another barrier: the intestinal wall.

The cells lining the digestive tract are designed to control what enters the bloodstream.

Many conventional drugs are small enough and chemically suited to cross cell membranes reasonably well.

Peptides tend to be larger and more water-soluble.

Those properties can make crossing the intestinal epithelium difficult.

A 2025 review summarized the two major problems clearly: peptides can be rapidly broken down by digestive proteases and often have low intestinal permeability because of their size and chemical properties.

So oral peptide delivery requires researchers to solve two difficult problems at once:

Keep the peptide intact.

And:

Get enough of it across the digestive barrier.

This Is Why Injection Has Traditionally Been Common

An injection bypasses most of the gastrointestinal system.

The peptide does not have to survive stomach acid, digestive enzymes, mucus, and intestinal absorption before reaching systemic circulation.

That makes injected delivery far more predictable for many peptide molecules.

It does not mean peptides are inherently “injectable substances.”

It means injection is one technical way pharmaceutical developers have overcome the digestive barriers faced by this class of molecules.

Delivery method and molecular identity are separate issues.

Scientists Have Been Trying to Make Oral Peptides for Decades

The appeal of an oral peptide medicine is obvious.

Most people would rather take a tablet than use an injection.

That has led to extensive research into technologies that protect peptides or improve their absorption.

Researchers have explored approaches including:

• protective coatings
• nanoparticles
• lipid carriers
• enzyme inhibitors
• absorption enhancers
• chemical modifications
• mucoadhesive systems
• receptor-mediated transport
• specialized capsules.

A recent review described oral delivery as one of the major continuing challenges in peptide and protein therapeutics because researchers must overcome stomach acidity, digestive enzymes, mucus, and the intestinal epithelial barrier.

There has been progress.

One particularly interesting example involves semaglutide.

Oral Semaglutide Shows That It Can Be Done

Semaglutide is a peptide-based GLP-1 receptor agonist.

An oral formulation was approved by FDA in 2019 for type 2 diabetes.

That might seem to prove that the peptide-pill problem has been solved.

It hasn’t.

Oral semaglutide works because the tablet includes a specialized absorption-enhancing compound called SNAC, short for sodium N-(8-[2-hydroxybenzoyl] amino) caprylate.

SNAC helps create a local environment in the stomach that protects semaglutide from enzymatic degradation and promotes absorption across the gastric epithelium.

The technology is a good demonstration of how much formulation science can be required to turn a peptide into a practical oral product.

Researchers didn’t simply take injectable semaglutide, press it into a tablet, and expect it to work.

They had to engineer the delivery system too.

Even Successful Oral Peptides Can Have Low Bioavailability

Bioavailability refers to how much of a compound reaches systemic circulation in a usable form.

For many oral peptide drugs, bioavailability is very low.

One recent review notes that fewer than 2% of FDA-approved peptide and protein drugs are formulated for oral delivery, largely because peptides are inefficiently absorbed and can be destroyed in the gastrointestinal tract.

Even successful oral peptide formulations may allow only a small fraction of the swallowed peptide to reach circulation.

That can still be useful if the drug and formulation have been carefully developed around that limitation.

But it shows why making a peptide pill is more complicated than making an ordinary tablet.

Peptide Engineering Can Help Too

Scientists don’t only modify the delivery system.

They can modify the peptide.

Changing particular amino acids may make a molecule harder for enzymes to recognize and destroy.

Researchers can also add chemical features that alter:

• stability
• protein binding
• membrane interactions
• circulation time.

Modern peptide engineering commonly uses approaches such as amino-acid substitution, cyclization, lipidation, and other structural modifications to improve stability and biological availability.

This means modern peptide development often involves two engineering problems:

Design the peptide.

Design a way to deliver it.

Retatrutide Is a Good Example of an Engineered Peptide

Retatrutide, also known as LY3437943, is an investigational peptide being developed by Eli Lilly.

It activates three receptor systems:

• GIP
• GLP-1
• glucagon.

Lilly describes retatrutide as a single triple hormone receptor agonist. As of September 2026, it remains investigational and has not been approved by any regulatory agency.

Retatrutide also illustrates how scientists can modify peptides to change how long they remain active in biological systems.

The molecule has been engineered for extended exposure, rather than behaving like a short-lived natural peptide hormone.

Researchers interested in the molecule itself can also study appropriately characterized retatrutide research peptide material in laboratory settings. Research material should not be confused with Lilly’s investigational clinical formulation or an approved medicine.

Why Not Just Make Every Peptide More Stable?

Because stability is only one part of the problem.

Changing a peptide can alter its biological activity.

Imagine that researchers replace an amino acid to make a peptide resistant to an enzyme.

That modification might improve stability.

But it could also:

• weaken receptor binding
• change receptor selectivity
• reduce solubility
• alter molecular shape.

Peptide development is therefore a balancing act.

Scientists want a molecule that survives long enough to work while still interacting correctly with its intended biological target.

The Stomach Isn’t the Only Challenge

The digestive tract presents several barriers in sequence.

Acid

The stomach is strongly acidic.

Some peptides can lose structural integrity or become more susceptible to degradation under these conditions.

Digestive Enzymes

Pepsin acts in the stomach, while pancreatic and intestinal enzymes continue peptide digestion further down the gastrointestinal tract.

Mucus

A peptide may then have to move through the mucus coating the intestinal surface.

Cell Membranes

Finally, it needs to cross the epithelial cell barrier to enter circulation.

An oral formulation that solves only one of these problems may still fail.

This is why newer research often combines several strategies rather than relying on a single trick.

Could Nanoparticles Solve the Problem?

Researchers are studying nanoparticles and other carrier systems that can surround or protect peptide molecules.

In theory, a carrier can shield a peptide from digestive enzymes, release it at a useful location, and improve transport across biological barriers.

Other researchers are investigating microscopic devices, specialized polymers, and targeted transport systems.

The field is active, but there is unlikely to be one universal oral-delivery technology that works for every peptide.

Different peptides have different:

• sizes
• charges
• structures
• solubilities
• stability profiles.

A delivery strategy that works well for one molecule may perform poorly with another.

Why Does This Matter Beyond Convenience?

Oral delivery isn’t only about avoiding needles.

A different route of administration can alter:

• absorption
• concentration over time
• tissue exposure
• variability between people.

These differences can change how a molecule behaves.

Scientists therefore cannot automatically assume that an oral form and an injected form of the same peptide will have identical pharmacokinetics.

The formulation becomes part of the pharmaceutical system.

Research Peptides Are a Different Question

People interested in peptide science sometimes encounter laboratory research peptides online.

It is important not to confuse these with approved oral or injectable medicines.

A research peptide is a laboratory material.

An approved drug has gone through a regulatory process involving laboratory work, animal research, human clinical trials, manufacturing review, and an evaluation of whether its benefits outweigh its known risks for a specific intended use.

Analytical purity alone does not bridge that gap.

A peptide can be chemically well characterized and still not be an approved medicine.

Will More Peptides Eventually Become Pills?

Probably.

The scientific tools are improving quickly.

Researchers now have better:

• absorption enhancers
• protective formulations
• peptide modifications
• nanoparticle systems
• manufacturing technologies.

The success of oral semaglutide demonstrates that some barriers can be overcome.

But the fact that oral peptide drugs remain relatively uncommon also shows how difficult the problem remains.

The future may include more oral peptides.

It may also include entirely new delivery technologies that look very different from today’s ordinary tablet.

Conclusion

Most peptide medicines aren’t pills because the human digestive system presents an unusually hostile environment for peptide molecules.

The stomach and intestine can break peptides apart.

And even intact peptides often have difficulty crossing the intestinal wall.

That creates a two-part challenge: protecting the molecule and getting enough of it into circulation.

Scientists are solving parts of that problem through peptide engineering, absorption enhancers, specialized formulations, nanoparticles, and other technologies.

Oral semaglutide proves that an oral peptide can work when the formulation is carefully engineered.

But it is the exception rather than evidence that peptide delivery has become easy.

For anyone interested in modern peptide science, this is one of the most important ideas to understand:

Sometimes discovering a biologically useful peptide is only half the work.

Scientists also have to figure out how to get it where it needs to go.

References

Chen G. Advances in the Oral Delivery of Protein and Peptide Drugs. Pharmaceutics. 2025.

Triplitt C, et al. Current Understanding of SNAC as an Absorption Enhancer: The Oral Semaglutide Experience. 2024.

Strategies for overcoming multiple barriers of oral administration of protein and peptide therapeutics. 2026.

Therapeutic peptides and proteins: Status and developments in drug delivery. 2026.